Prior to joining Rebiotix/Ferring, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridioides difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

Dr. Bancke joined Rebiotix in 2018 with a strong background in clinical development and strategic leadership at biotech and mid-size pharmaceutical companies.  Her clinical and program leadership experience spans first-in-human studies to global Phase 3 trials, as well as products with orphan designation, fast track status, and unique regulatory pathways.

Prior to joining Rebiotix, Dr. Bancke spent 10 years at Upsher-Smith Laboratories, leading clinical trials and research strategy, as well as cross-functional development programs for both ANDA and NDA products.  Most recently, she was the Clinical and Development Program Lead at Proximagen, a privately-held biotech company focused on small molecule drug discovery and development.  At Proximagen, Dr. Bancke led an early-phase neuro-oncology program, as well as a late-stage epilepsy product preparing for NDA submission. Dr. Bancke received her undergraduate degree in biology from the University of Nebraska–Lincoln and earned a PharmD from the University of Nebraska Medical Center, after which she completed a post-doctoral fellowship in clinical research.

Mr. Willard has led commercial teams for pre-launch, launch, and co-promotion initiatives for both large and small companies in the pharmaceutical and biotech arenas, as well as providing commercial strategy to improve a company’s value. Additionally, Mr. Willard’s experience includes strategic brand planning, business development, market research, and product platform strategy as part of pre-approval packages, new market entries and product life cycle management.

Mr. Willard received his undergraduate degree in Microbiology and Immunology from Purdue University, as well as his MBA in Marketing/Corporate Strategy from Clemson University.

Mr. King is also well-versed in product development technologies, including fermentation, formulation and assay development, all under the umbrella of International Council for Harmonization (ICH) guidelines and Quality by Design (QbD) programs. These arenas lend well to Mr. King’s leadership in developing the Chemistry, Manufacturing and Controls (CMC) documents needed to bring new microbiome-based technologies forward to regulatory agencies as part of the product approval process.

Prior to joining Rebiotix, Mr. King held a range of positions in Research, Quality, and Technical Operations, supporting the missions of large and small corporations, including BioThera and MannKind Corporation. Mr. King is also the founder of Sand Dollar Consulting, LLC, specializing in process development, phase-appropriate quality systems and CMC regulatory submissions for early stage biologic products.

Mr. King received his undergraduate degree in Biochemistry from Virginia Tech, and his Masters of Science in Biochemical Engineering from the Massachusetts Institute of Technology.

Prior to joining Rebiotix, she held multiple Quality leadership positions at Integer Holdings, driving product approvals and compliance initiatives for Class III, II and combination products. As part of her extensive experience, Ms. Markus also spent 15 years in the generic Rx pharmaceutical industry at Perrigo, formerly Paddock laboratories, including roles from QC Microbiology to leading Quality Commercial Operations with a focus on leading teams to provide Quality oversight and delivery of new product approvals from product development to commercialization.

Ms. Markus obtained her Bachelor of Science degree in Microbiology and Chemistry from North Dakota State University, in Fargo, ND.  Ms. Markus’s passion is to maximize results and improvements, while building relationships with people to achieve complex, strategic and on-time results.

Prior to joining Rebiotix, Ms. Wall led the Operations team at DiaSorin Inc, an Invitro-Diagnostics company.  Through many roles and responsibilities, from Reagent Manufacturing to Quality Control, Tech Transfer and Engineering, she spent her career successfully transferring newly developed products into industrial scale manufactured products, developing and leading great people along the way.

Ms. Wall obtained her Master of Science degree in Manufacturing System Engineering from the University of St. Thomas, in St. Paul, MN.  A dream of being a scientist starting in the 4^th grade led her to complete her undergraduate work in Biotechnology at the University of Minnesota – Mankato working in a diabetes research laboratory.